Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr. Lal PathLabs's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was ₹2,350 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹7,411 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Dr. Lal PathLabs's annualizedROC % for the quarter that ended in Jun. 2026 was 33.82%.
Dr. Lal PathLabs's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 191.91%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Dr. Lal PathLabs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 2.35%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs EBIT Related Terms
Dr. Lal PathLabs EBIT Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹7,411 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a EBIT of ₹7,411 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dr. Lal PathLabs.
Is Dr. Lal PathLabs' EBIT too high?
Dr. Lal PathLabs' current EBIT is ₹7,411 Mil. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' EBIT compare to TMO and DHR?
Dr. Lal PathLabs' EBIT of ₹7,411 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dr. Lal PathLabs. Dr. Lal PathLabs's current EBIT is ₹7,411 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current EBIT is ₹7,411 Mil. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current EBIT is ₹7,411 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
EBIT: ₹7,411 Mil
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
